Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 7/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490469 | 0.78 | ADORA2A (0.37) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL3857168 | 0.78 | ADORA1 (0.60) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL1445604 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL9710158 | 0.74 | — | — | |
| SCHEMBL5403761 | 0.74 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11033550 | 0.72 | ADORA2A (0.45) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11269779 | 0.71 | ADORA2A (0.66) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10387483 | 0.69 | ADORA2A (0.45) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10387490 | 0.67 | TLR7 (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3210897 | 0.67 | ADORA2A (0.35) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1201678-B1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | SANKYO CO (JP) | 2004-09-22 | — | — | EP | claimed |
| US-20110082101-A1 | COMBINATIONS COMPRISING EPOTHILONES AND ANTI-METABOLITES | HOHNEKER JOHN ARTHUR | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082101-A1 | COMBINATIONS COMPRISING EPOTHILONES AND ANTI-METABOLITES | EPOR, POLN, TPMT | ADORA2A 1286/4885ADORA1 1450/4885YTHDC1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.